Brief: Aurinia Presents Data Reinforcing Lupkynis® Safety And Efficacy For People With Lupus Nephritis At Congress Of Clinical Rheumatology East 2024
09/05/2024 12:45
May 9 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O :
* AURINIA PRESENTS DATA REINFORCING LUPKYNIS® SAFETY AND
EFFICACY
FOR PEOPLE WITH LUPUS NEPHRITIS AT CONGRESS OF CLINICAL
RHEUMATOLOGY EAST 2024
Source text for Eikon: ID:nBw7mDhbpa
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death